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The development of drugs for neglected infectious diseases often uses parasite-specific enzymes as targets. We
here demonstrate that parasite enzymes with highly conserved human homologs may represent a promising
reservoir of new potential drug targets. The cyclic nucleotide-specific phosphodiesterases (PDEs) of
Trypanosoma brucei, causative agent of the fatal human sleeping sickness, are essential for the parasite. The
highly conserved human homologs are well-established drug targets. We here describe what is to our knowledge
the first pharmacological validation of trypanosomal PDEs as drug targets. High-throughput screening of
a proprietary compound library identified a number of potent hits. One compound, the tetrahydrophthala-
zinone compound A (Cpd A), was further characterized. It causes a dramatic increase of intracellular cyclic
adenosine monophosphate (cAMP). Short-term cell viability is not affected, but cell proliferation is inhibited
immediately, and cell death occurs within 3 days. Cpd A prevents cytokinesis, resulting in multinucleated,
multiflagellated cells that eventually lyse. These observations pharmacologically validate the highly conserved
trypanosomal PDEs as potential drug targets.
Kinetoplastid protozoa (Kinetoplastida, Excavata [1])
cause severe diseases of humans and/or their domestic
animals. In sub-Saharan Africa, the fatal human
African trypanosomiasis (HAT, sleeping sickness) is
caused by Trypanosoma brucei subspecies and threat-
ens 38 countries. The therapeutic armamentarium
against sleeping sickness and many other protozoan
infections is extremely limited and ineffective, with
almost no new drugs introduced for decades [2]. In
addition, the standard medication against late-stage
sleeping sicknessdmelarsoproldis encountering
increasing problems with drug refractoriness [3, 4].
Although many compounds with antiparasitic activity
have been reported, new paradigms are required for
a more efficient development of urgently required
antiparasite chemotherapies.
The development of antiparasitic compounds has
long focused on parasite-specific targets. This approach
has generated some promising lead compounds [5–7]
but often encountered difficulties during the transi-
tion from basic research to drug development. We here
show that a class of enzymes whose catalytic domains
are highly conserved between T. brucei and its human
host, the cyclic nucleotide-specific phosphodiesterases
(PDEs), are promising drug targets. Human PDEs are
being intensely investigated as drug targets for nu-
merous clinical conditions, and several PDE-inhibitor
based drugs are on the market [8]. The genomes of
T. brucei and all other kinetoplastids were analyzed to
date code for 4 distinct PDE families (PDEs A–D; [8]).
Their catalytic domains are structurally highly simi-
lar to those of the human PDEs ([10]; Hengming Ke,
University of North Carolina, personal communi-
cation, September 2010). In T. brucei, the PDE-B
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family consists of 2 highly similar enzymes (75.3% overall
sequence identity) that are coded for by 2 tandemly arranged
genes (located on chromosome 9 in the T. brucei genome;
[9]). Despite their similarity, TbrPDEB1 and TbrPDEB2
show distinct subcellular localizations [10]. The 2 enzymes
TbrPDEB1 and TbrPDEB2 are the predominant controlling
elements of intracellular cyclic adenosine monophosphate
(cAMP) levels, and their disruption by RNA interference
(RNAi) both dramatically increases intracellular cAMP and
induces complete trypanosome cell lysis, both in culture and
in vivo [11]. The current study identifies a class of potent
small-molecule inhibitors of TbrPDEB1 and TbrPDEB2 by
high-throughput screening of a chemical library. A repre-
sentative compound, compound A (Cpd A), causes a rapid
and sustained elevation of intracellular cAMP that leads to
parasite cell death through inhibition of cytokinesis during
cell division. Because PDEs are highly conserved between
host and parasite, and because human PDEs are well-ex-
plored drug targets, using parasite PDEs as drug targets al-
lows exploitation of the existing vast expertise in developing
PDE inhibitors against human PDEs. The study thus dem-
onstrates that parasite enzymes that are highly similar to
well-studied human drug targets represent an interesting
reservoir of new parasitic drug targets. Using this strategy,
we identified PDE inhibitors as a new generation of trypa-
nocidal agents that represent a completely new chemical class
and show no cross-resistance with existing drugs.
MATERIALS AND METHODS
Strains and Cultures
The trypanosome line used was strain MiTat1.2(221) [12].
Strain TbAT1KO was constructed by deletion of the TbAT1/P2
transporter from MiTat1.2(221) and consequently was resistant
to the veterinary trypanocide diminazene [13, 14]. Strain B48
was derived from TbAT1KO by stepwise adaptation to pent-
amidine in vitro and has lost the high-affinity pentamidine
transporter [15], rendering it highly resistant to both pentami-
dine and melarsoprol [16]. Strains were grown as bloodstream
forms in HMI-9 medium [17]. Ex vivo parasites were purified
from whole rat [18], and purified trypanosomes were main-
tained in HMI-9 medium.
High-Throughput Screening
A proprietary library of .400 000 compounds was screened
using a homogenous assay that determines [3H]-cAMP hy-
drolyzing PDE activity by scintillation proximity assay
(SPA). In a first step, PDE activity hydrolyzes [3H]-cAMP
into [3H]-5#AMP. In a second step, substrate and product
are distinguished by addition of SPA yttrium silicate beads
(GE Healthcare). In the presence of zinc sulfate, the linear
[3H]-5#AMP binds to the beads, whereas the cyclic [3H]-
cAMP does not. Close proximity of bound [3H]-5#AMP then
allows radiation from the tritium to the scintillant within
the beads, resulting in a measurable signal, whereas the un-
bound, hence distant [3H]-cAMP does not generate this sig-
nal. The enzymatic reaction was conducted in a total assay
volume of 100 lL, comprising 20 mmol/L Tris (pH 7.4)
supplemented with bovine serum albumin (0.1 mg mL21) and
5 lmol/L Mg21 in the presence of 0.5 lmol/L cAMP substrate,
containing 50 000 cpm of [3H]-cAMP, and test compound.
Recombinant TbrPDEB1 was added in a quantity that re-
sulted in 10%–20% hydrolysis of cAMP. The reaction was
initiated by adding the substrate, followed by an incubation
for 15 minutes at 37C. Adding SPA beads with zinc sulphate
(50 lL) terminated the reaction, and the SPA signal was
analyzed by standard luminescence detection devices.
The final concentration of solvent (1% dimethyl sulfoxide
[DMSO]) was identical in all assays and did not affect
enzymatic activity. In the initial screening campaign, all
compounds were added at 10 lmol/L. Compounds showing
$50% inhibition of TbrPDEB1 activity were retested. The
Z factor was 0.716 in the primary screen and 0.740 in the
retesting of positive candidates. About 600 compounds
showed half-maximal inhibitory concentration (IC50) values
for TbrPDEB1 inhibition of #5 lmol/L.
Expression of Recombinant TbrPDEB1
TbrPDEB1 was expressed in SF21 insect cells. TbrPDEB1
complementary DNA was amplified by polymerase chain
reaction (PCR) and cloned into the pCR-Bac vector (In-
vitrogen). SF21 cells were infected with a high-titer virus
supernatant, and infected cells were cultured for 48–72 hours
to allow optimal protein expression. Cells were collected in
20 mmol/L Tris pH 8.2, 140 mmol/L sodium chloride,
3.8 mmol/L potassium chloride, 1 mmol/L ethylene glycol
tetraacetic acid, 1 mmol/L magnesium chloride2, 10mmol/L ß-
mercaptoethanol, 2 mmol/L benzamidine, 0.4 mmol/L Pefa-
bloc, 10 lmol/L leupeptin, 10 lmol/L pepstatin A, and
5 mmol/L soybean trypsin inhibitor. After sonication, a 1000
g supernatant was used for enzyme assays.
Determination of PDE Activity
PDE activity of Triton X-100 lysates of whole trypanosomes
or of recombinant enzyme was determined by published
procedures [19, 20]. Enzyme concentrations were always
adjusted so that ,20% of substrate was consumed. Blank
values (measured in the presence of denatured protein) were
always ,2% of total radioactivity.
Cell Proliferation Assay
Test compounds were serially diluted in 96-well plates
in HMI-9 medium [21]. After 48 hours of incubation, 20 lL
of 0.5 mmol/L resazurin in phosphate-buffered saline (PBS)
was added. Fluorescence was measured after an additional
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24 hours with excitation and emission filters of 544 and
590 nm, respectively. The detailed assessments of efficacy
against T. brucei strains of differing drug sensitivities, and
comparing Cpd A with a panel of established trypanocides,
were performed at the University of Glasgow.
Enzyme-Linked Immunosorbent Assay for Direct Quantification
of Intracellular cAMP Concentration
Intracellular cAMP concentrations were quantified by enzyme-
linked immunosorbent assay, using the Direct Cyclic AMP
Enzyme Immunoassay kit (Assay Designs). Bloodstreams from
trypanosomes were cultured in vitro and incubated at 37C
with or without test compounds at a density of 53 106 cells/mL.
At predetermined time points, 2-mL samples were centrifuged
at 855 g for 10 minutes at 4C. The supernatant was removed,
and the cell pellet was resuspended in 100 lL of 0.1 mol/L
hydrochloric acid. After centrifugation at 16 000 g for 10
minutes, the supernatant was removed and stored at 220C.
The cAMP content was assessed by enzyme-linked immuno-
sorbent assay, according to the manufacturer’s instructions.
Samples were taken in duplicate, and all assays were con-
ducted independently $3 times.
Determination of In Vivo [3H]-cAMP Synthesis
Ex vivo bloodstream trypanosomes were obtained from infected
rats and resuspended in HMI-9 medium containing 10% fetal
calf serum (FCS) medium (with 100 lmol/L inosine substituted
as the purine source instead of hypoxanthine as the latter might
block [3H]-adenine incorporation). [3H]-adenine (40 lCi) was
added, and the cultures were incubated at 37C, 5% carbon
dioxide (CO2) for 2 hours. Cells were then washed 3 times with
10 mL of HMI-9/10% FCS (1inosine, -hypoxanthine) and
finally resuspended to give a cell density of 1 3 108 trypano-
somes/mL. At predetermined times, 0.5-mL samples were taken
and quenched by adding an equal volume of ice-cold 5% tri-
chloroacetic acid containing 1 mmol/L adenosine triphosphate
(ATP) and 1 mmol/L cAMP. Samples were centrifuged at 16 000
g for 2 minutes, and the supernatants stored at 220C until
[3H]-cAMP extraction.
Columns loaded with 2 mL of Dowex 50WX4-400 ion-
exchange resin (Sigma) were placed above 20 mL scintillation
vials, and the supernatant samples were loaded onto columns. In
total, 3 mL of water was added to the column to elute [3H]-ATP
and [3H]–adenosine diphosphate. The columns were then placed
above a corresponding set of alumina columns prewashed with
0.1 mol/L imidazole, and 10 mL of water was added to each
Dowex column to transfer the remaining [3H]-adenine nucleo-
tides onto the alumina column. The alumina columns were then
mounted above a fresh set of 20-mL scintillation vials. The [3H]-
cAMP was eluted from the alumina with 6 mL of 0.1 mol/L
imidazole. Then 8 mL of scintillation fluid was added to each
vial, and radioactivity was determined by scintillation counting.
Intracellular [3H]-cAMP levels were expressed as a percentage of
the total pool of [3H]-adenine nucleotides.
Cell Lysis Assay
This assay was performed essentially as described by Gould et al
[21]. Briefly, 100 lL of HMI-9 medium containing twice the
desired concentration of test compound and 18 lmol/L propi-
dium iodide was added to a well of a 96-well plate; a well con-
taining 100 lL of medium with propidium iodide only was set up
as a control. An equal volume of medium containing blood-
stream-form trypanosomes was added to each well to give a final
cell density of 53 106/mL and propidium iodide concentration of
9 lmol/L. Fluorescence was monitored over time at 37C and 5%
CO2 using a FLUOstar OPTIMA fluorimeter with excitation and
emission filters at 544 and 620 nm, respectively.
Cell Death Assay
Bloodstream form trypanosomes were diluted in fresh HMI-9
medium to a cell density of 53 105 trypanosomes/mL to which
the required volume of test compound, diluted in DMSO, was
added to give the desired final concentration. Cultures were
incubated at 37C and 5% CO2. Samples were taken periodically
and assessed for cell density using a hemocytometer and a phase-
contrast microscope at 400-fold magnification.
Cell Cycle Analysis Using Flow Cytometry
Cells were incubated with the test compounds in HMI-9 me-
dium. After collection by centrifugation for 10 minutes at 610 g,
cell pellets were suspended in 70% methanol–30% PBS at 4C
overnight. After storage, the cells were washed twice in PBS by
centrifugation at 855 g for 10 minutes, finally being resuspended
in PBS containing 10 lg/mL propidium iodide and ribonuclease
A. The fixed cells were then incubated for 1 hour in the dark at
room temperature. Finally, flow cytometry was performed using
a Becton Dickinson FACSCalibur flow cytometer and using the
FL2-A detector with an amplification gain of 1.75.
Nucleus/Kinetoplast Configuration Assessment Using
Fluorescence Microscopy
Culture aliquots were spread onto glass slides. After drying, they
were fixed overnight in methanol at 220C. After rehydration in
PBS, slides were stained with 50 lL of PBS containing 1 lg/mL
4,6-diamidino-2-phenylindole (DAPI) and 1% (wt/vol) 1,4-
diazabicyclo[2.2.2]octane (DABCO) and analyzed using a Zeiss
Axioskop microscope (excitation wavelength 365 nm; emission
wavelength 445 nm). For each sample, .500 cells were analyzed.
Cells were manually scored and assigned to the following
categories: 1N1K (1 nucleus 1 1 kinetoplast; G1-phase cells);
1N2K (1 nucleus 1 2 kinetoplasts; early S-phase); 2N2K-early
(2 nuclei 1 2 kinetoplasts, no cleavage furrow; late mitosis);
2N2K-late (2 nuclei 1 2 kinetoplasts, with cleavage furrow;
ongoing cytokinesis); and .2N2K (aberrant cells with .2 nuclei
and 2 kinetoplasts).
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Mouse Infections
Young adult female NMRI mice were infected intraperitoneally
with 5 3 105 bloodstream-form trypanosomes per animal.
Parasitemia was monitored daily in tail blood and reached
.108/mL at day 4 in animals infected with control trypano-
somes. All experiments were conducted under the rules and
regulations on animal experimentation issued by the Swiss
federal authorities and regularly inspected by the Committee on
Animal Experimentation.
RESULTS
Two highly similar PDEs from T. brucei, TbrPDEB1 and
TbrPDEB2, are essential for parasite survival in vitro and in
vivo [11]. The extensive structural conservation between
human and trypanosome PDEs [22, 23] (Hengming Ke,
University of North Carolina, personal communication)
allows the exploitation of current technology and expertise
developed for human PDE inhibitors to be applied against
parasitic diseases. Accordingly, a proprietary compound library
(400 000 compounds; Nycomed Pharma) was screened with
recombinant TbrPDEB1. Hits were defined as compounds
that inhibited enzyme activity by .50% at 10 lmol/L; 600
hits were identified. All of the highly potent inhibitors
belonged to 2 main chemical classes: the 4-phenyl-4a,5,8,8a-
tetrahydrophthalazinones and the 4-phenyl-4a,5,6,7,8,8a-
hexahydrophthalazinones (Figure 1A). For 35 hits, the potency
to inhibit recombinant TbrPDEB1 (IC50) was correlated with
the potency to suppress trypanosome proliferation (half-
maximal effective concentration [EC50]) (Figure 1B). The
tetrahydrophthalazinone Cpd A was identified as the most
potent inhibitor of TbrPDEB1 (IC50, 10 nmol/L; Figure 1C),
and it also inhibited the isoenzyme TbrPDEB2 with similar
potency (see Figure 4A). For these and all subsequent
experiments, Cpd A was used in a racemic form. Inhibition of
TbrPDEB1 and TbrPDEB2 by Cpd A was closely paralleled by
the suppression of trypanosome proliferation (Figure 1D).
Cpd A has been disclosed as a potent inhibitor of human
PDE4 (IC50, 0.6 nmol/L; example 16n in reference [24]).
Cpd A inhibits cell proliferation with an EC50 of
30–70 nmol/L (depending on strain, inoculum density,
growth medium, etc), similar to that of the trypanocides
suramin or diminazene, and it is $10-fold more active than
nifurtimox (Figure 2A). In addition, Cpd A is 200-fold
more potent than dipyridamole, currently the most potent
inhibitor of both TbrPDEB1 and TbrPDEB2 activity [25].
Because resistance to diamidine and melaminophenyl
arsenical drugs is an increasing problem [3, 4], Cpd A was
Figure 1. A, Structure A: 4-phenyl-4a,5,8,8a-tetrahydrophthalazinone; structure B: 4-phenyl-4a,5,6,7,8,8a-hexahydrophthalazinone. B, Correlation
between TbrPDEB1 inhibition and trypanocidal activity by compounds of different chemical classes identified in the high-throughput screening. A best-fit
line was calculated using linear regression (r2 5 .6), and 95% confidence intervals are indicated by dotted lines. EC50, half-maximal effective
concentration. C, Structure of compound A (Cpd A). Inset indicates half-maximal inhibitory concentration (IC50) values (nmol/L) of Cpd A against TbrPDEB1
and human PDE4. D, In vitro trypanocidal activity of Cpd A assessed using Alamar blue (filled circles) or microscopic cell counts (open circles). After 72-
hour incubation with the indicated drug concentrations. The EC50 values were 18 and 15 nmol/L, respectively, for the experiment shown.
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tested for potential cross-resistance, using 2 well-defined cell
lines resistant to the most important trypanocides in clinical
and veterinary use today. TbAT1-KO [16] and B48 [17] are
strongly resistant to diminazene (TbAT1-KO) and to all
diamidine and melaminophenyl arsenical trypanocides
(B48). These multidrug-resistant cell lines were as sensitive
to Cpd A as were wild-type cells (Figure 2B).
High intracellular cAMP concentrations are lethal for
bloodstream-form trypanosomes [11]. This effect can also be
mimicked by membrane-permeable cAMP analogs such as
8-(4-chlorothiophenyl)-cAMP, 8-bromo-cAMP, or N6,O2’-
dibutyryl-cAMP, which all inhibit cell proliferation at low
micromolar concentrations. This apparent inhibition of cell
proliferation by the cAMP analogs is due to progressive cell
lysis, similar to what was observed when RNAi against
TbrPDEB1 and TbrPDEB2 was induced [11], or after ex-
posure of cells to Cpd A. Exposure of cultured trypanoso-
mes to Cpd A for 3 hours raised intracellular cAMP levels
44-fold, from 3.3 6 0.2 to 146 6 12 pmol/108 cells (P , .01,
Figure 3A). In contrast, the low-potency PDE inhibitors
dipyridamole (40 lmol/L) and etazolate (100 lmol/L) [25]
did not induce significant changes in intracellular cAMP
concentrations.
The effects of Cpd A are both time and concentration de-
pendent. At 1 lmol/L Cpd A, cAMP levels increased linearly
over 9 hours (Figure 3B). This response is concentration de-
pendent, and even at 30 nmol/L, Cpd A raised cAMP signif-
icantly (Figure 3C). The action of Cpd A occurs extremely
rapidly, as determined using [3H]-adenine prelabeled cells
(see Materials and Methods). The concentration of cAMP
Figure 2. A, Comparison of cell proliferation inhibition by compound A
(Cpd A) and by other trypanocides. Diminazene aceturate (diamonds),
suramin (squares), Cpd A (crosses), nifurtimox (filled circles) dipyridamole
(open circles). Diminazene, suramin, and nifurtimox are clinically used
antitrypanosomal drugs. Panel represents a single experiment that is
representative of 4 identical but fully independent experiments. B,
Trypanosome lines resistant to diminazene and pentamidine do not exhibit
cross-resistance to Cpd A. B28 carries resistance to pentamidine. EC50,
half-maximal effective concentration; TbAT1-KO, drug-resistant derivative
of MiTat1.2(221) that is resistant to diminazene [16]; wt, wild-type
bloodstream forms of MiTat1.2(221). *Not significantly different from wt;
**P , .05, ***P , .01, ****P , .001.
Figure 3. A, compound A (Cpd A) (A ) increases intracellular cyclic
adenosine monophosphate (cAMP) levels more potently than 100 lmol/L
etazolate (B ) or 40 lmol/L dipyridamole (C ). Dimethyl sulfoxide (DMSO)
control is given in D. Bar chart shows the intracellular cAMP concentration in
bloodstream-form trypanosomes incubated with the compounds for 3 hours.
Each experiment was performed in duplicate. Bars represent means (and
standard error of the mean) for 3–4 independent experiments. P values were
calculated using 2-tailed paired Student t test. **P, .01. B, Time-dependent
cAMP increase in trypanosomes incubated with 1 lmol/L Cpd A (filled
squares ) and in a control culture (DMSO only) (open squares ). Data shown
are means for 3 independent experiments; error bars indicate standard
errors. C, Concentration dependence of cAMP accumulation. Trypanosomes
were incubated with Cpd A at the indicated concentrations for 3 hours, and
cAMP levels were determined by enzyme-linked immunosorbent assay.
*P , .01; ***P , .001 (2-tailed unpaired Student t test). D, Effect of
0.3 lmol/L Cpd A on intracellular cAMP levels in bloodstream-form
trypanosomes (ex vivo) prelabeled for 2 hours with [3H]-adenine. Cells were
incubated with (squares) or without (circles) Cpd A at a cell density of
1 3 108/mL in HMI-9 medium at 37C. Graph shown is representative of
3 separate experiments performed in triplicate. Data are expressed as fold
difference relative to 0-minute control value, with standard errors.
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increased almost instantaneously after adding the compound
(Figure 3D), demonstrating that Cpd A enters the cell rapidly
and acts primarily by inhibiting PDE activity. To our knowledge,
these results for the first time demonstrate the crucial role of
trypanosomal PDEs in maintaining a constant low level of
cAMP, counteracting a high constitutive level of cAMP synthe-
sis [26]. Although Cpd A inhibited TbrPDEB1 and TbrPDEB2
with similar IC50 values of 12 nmol/L, the IC50 value for in-
hibiting total cellular PDE activity was 70 nmol/L (Figure 4A).
At 1 lmol/L, Cpd A inhibited total PDE activity completely,
in contrast to several reference PDE inhibitors that showed no
effect at this concentration (Figure 4B).
Despite its rapid effect on cAMP, Cpd A had no observable
effect on cell integrity for $15 hours, even at 3 lmol/L
(1503 EC50) as determined by a cell lysis assay [21] (Figure 5A).
Cell lysis is a slow process, reaching completion after 42 hours (at
10 lmol/L Cpd A) to 55 hours (at 1 lmol/L Cpd A; Figure 5B).
To explore cell cycle effects, trypanosomes cultured in the
presence or absence of 1 lmol/L Cpd A were analyzed by flow
cytometry. Control cultures displayed a constant distribution
between diploid (2C) and tetraploid (4C) cells (Figure 6). In
Cpd A-treated cells, the relative numbers of tetraploid cells
increased progressively, whereas diploid trypanosomes di-
minished steadily over time. The data show that elevated
cAMP levels did not immediately affect DNA synthesis but
block cell cycle progression. The accumulation of higher
ploidy cells (.4C) at longer incubation times suggests that
Figure 5. A, Cell lysis after exposure to various concentrations of
compound A (Cpd A). Trypanosomes were incubated in medium containing
9 lmol/L propidium iodide (PI) and varying concentrations of Cpd A.
Fluorescence was continuously monitored (excitation: 544 nm; emission
620 nm). Slow upward slope of traces corresponding to the control and
low concentrations of Cpd A reflects gradual entry of PI into live, intact
trypanosomes. Background fluorescence from unbound PI was subtracted.
The experiment is representative of several independent experiments.
B, Growth inhibition and cell lysis induced by Cpd A. Separate
trypanosome cultures at starting densities of 4 3 105 cells/mL were
incubated with 1 lmol/L (open squares ) or 10 lmol/L (filled squares ) Cpd
A. Control culture with the same starting density was run in parallel
without drug (inset ). Cell densities were determined by microscopic
counts (in duplicate) in a hemocytometer. At both concentrations tested,
Cpd A induces complete cell lysis, albeit with different time courses.
Panel displays a single experiment representative of several similar,
independent experiments.
Figure 4. A, Potency of compound A (Cpd A) against total cellular
phosphodiesterase (PDE) activity (filled squares) (half-maximal inhibitory
concentration (IC50), 76.6 nmol/L), TbrPDEB1 (open circle) (IC50, 12.4 nmol/
L) and TbrPDEB2 (filled circles) (IC50,12.0 nmol/L). All assays were
performed in triplicate, and figure represents 1 of 2 independent
experiments that produced essentially identical results. The slightly
higher IC50 values (compared with Figure 1C; 12 vs 3.8 nmol/L) most likely
reflect different enzyme sources used (Figure 1C, expression in SF2 cells;
this figure, expression in Saccharomyces cerevisiae ). B, Total cellular PDE
activity inhibited at 1 lmol/L inhibitor concentration, comparing activity
of Cpd A with that of reference PDE inhibitors. DMSO, dimethyl sulfoxide.
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DNA synthesis, and possibly nuclear division, continue but
without intervening cytokinesis. Fluorescence microscopy
analysis of cells fixed after 12 hours of Cpd A treatment
confirmed that nuclear division did take place and identified
the abscission into 2 daughter cells, after near-completion of
cytokinesis, as the specific defect induced by Cpd A-elevated
cAMP levels. Cells were manually scored for numbers of
nuclei (N) and kinetoplasts (K) and assigned to the follow-
ing categories: 1N1K, 1N2K, 2N2K-early, 2N2K-late, and
.2N2K (for definitions see Materials and Methods and
Figure 7A–F).
For trypanosomes incubated with 1 lmol/L Cpd A, the
percentage of cells in the 1N1K category (G1-phase) was reduced
to 34%, compared with 74.4% in the control (Figure 7I). In
contrast, percentages of 2N2K (late mitosis/cytokinesis) and
.2N2K cells were both dramatically increased in the Cpd
A-treated population. When the 3 categories corresponding to
the normal cell cycle stages (1N1K, 1N2K, and 2N2K-early) were
combined, this category decreased from 90.3% (controls) to
42.9% (P , .01) after Cpd A treatment. This was balanced by
a corresponding increase in the 2N2K-late and .2N2K (aber-
rant cells) categories, from 9.7% (controls) to 57.1% (Cpd A
treated; P , .001). At longer Cpd A treatments, cells become
spherical, multinuclear, and multiflagellated, and they eventu-
ally lyse. This is very similar to what is seen when RNAi is
induced against TbrPDEB1 and TbrPDEB2: after induction of
RNAi, the cells gradually accumulate several nuclei, several ki-
netoplasts, and numerous flagella and finally become rounded
before eventually lysing (Figure 7G and 7H).
To verify whether Cpd A-mediated cell destruction also
reflects the complete elimination of trypanosome infectivity,
cells were treated in vitro with 25 or 250 nmol/L Cpd A for
48 hours before infection. Groups of 5 mice were inoculated
with 5 3 105 trypanosomes via intraperitoneal injection.
Control trypanosomes incubated with vehicle alone caused
a parasitemia of 3 3 108 cells/mL by day 4 postinfection. In
contrast, trypanosomes preincubated with 250 nmol/L Cpd A
were completely unable to initiate an infection. Even a pre-
incubation with as little as 25 nmol/L Cpd A (ie, 0.5 3 EC50)
dramatically reduced infectivity, with just a mild parasitemia
of 5 3 106/mL reached at day 6 after infection.
We conclude that sustained high cAMP levels disrupt cell
cycle regulation and inexorably lead to trypanosome death.
This course of events is similar whether PDE activity is re-
duced with a druglike inhibitor, such as Cpd A, or by RNAi
[11]. Elevated cAMP apparently has no immediate lethal
effect on the cells, even at 10–100-fold excess over normal
levels, but it specifically interferes with cell cycle control
mechanisms, principally abscission, leading to a protracted
but no less certain cell death.
DISCUSSION
This study for the first time, to our knowledge, establishes the
concept of choosing as a drug target a parasite enzyme whose
catalytic domain is highly conserved with human homologs
that are already well explored as drug targets. Human PDEs
enjoy a long story as successful drug targets, and several PDE
inhibitors are on the market as medication for a wide spectrum
of clinical conditions (including the human PDE3 inhibitor
cilostazol (Pletal; Otsuka Pharma; for intermittent claudication),
the PDE4 inhibitor roflumilast (Daxas; Nycomed Pharma; for
Figure 6. Flow cytometry analysis of the DNA content of trypanosomes grown in the presence and absence of 1 lmol/L compound A (Cpd A). Cells
were incubated under standard culture conditions in the absence (top row ) or presence (bottom row ) of 1 lmol/L Cpd A. Samples were taken every
4 hours for 24 hours. Histograms indicate the number of cells with particular fluorescence intensities (that correlate with their DNA content). Peaks
labeled 2C represent diploid cells; those labeled 4C represent cells that have replicated their DNA but have not yet undergone cytokinesis and thus are
tetraploid. Longer incubations with Cpd A cause an increase in cells with .4C DNA content. FL2-Area: total fluorescence emission.
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chronic obstructive pulmonary disease) or the PDE5 inhibitors
sildenafil (Viagra; Pfizer), tadalafil (Cialis; Lilly ICOS) or
vardenafil (Levitra; Bayer); for erectile dysfunction). Thus,
a vast experience of developing PDE inhibitors from screening
to registration is available and can be tapped for the deve-
lopment of parasite-specific PDE inhibitors. Issues concerning
parasite-vs-host specificity can be addressed using the prowess
of medicinal chemistry, combined with new structural informa-
tion that the PDE catalytic domains show interesting parasite-
specific structural features that could be exploited for rendering
compounds more parasite-specific [22]. This approach of
repurposing the available know-how and technology for
human PDE inhibitors toward developing parasite-specific
compounds may help break the deadlock between the urgent
medical need for new antiparasitic drugs and the techno-
logical and financial obstacles to developing them.
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Figure 7. Images of trypanosomes incubated for 12 hours with 1 lmol/L compound A (Cpd A). Cells were stained with diamidino-2-phenylindole (DAPI)
and were categorized as follows: A, Cell with 1 nucleus and 1 kinetoplast (1N1K). B, Cell with 1 nucleus and 2 kinetoplasts (1N2K). C, Cell with 2 nuclei
and 2 kinetoplasts but before a cleavage furrow has started to divide the mother and the daughter cells (2N2K–early [E]). D, 2 nuclei and 2 kinetoplasts,
but with cell division almost completed (2N2K–late [L]). E, Cell with replicated and segregated nuclei and kinetoplasts and complete cleavage furrow but
not having completed mother-daughter cell separation before replicating 2 more kinetoplasts (2N4K). Arrows: kinetoplasts. F, Cell with 4 nuclei and 4
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of image ) having made progress toward a further cell division. G, H, Normal trypanosomes before (G ) and multiflagellated cells after (H ) inducing RNA
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staining of nuclei and kinetoplasts (blue). I, Percentages of cells in the various nucleus-kinetoplast configurations.
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